首页 > 抗体蛋白 > 抗体
PE anti-rat CD90/mouse CD90.1 (Thy-1.1) Antibody
产品名称:
PE anti-rat CD90/mouse CD90.1 (Thy-1.1) Antibody
产品类别:
抗体
产品编号:
202523
产品应用:
202523
[价格]
规格 价格 库存
50µg ¥ 876 1

产品详情

Product Details

Verified Reactivity
Rat, Mouse
Reported Reactivity
Rabbit, Guinea Pig
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Rat thymocyte Thy-1 antigen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The OX-7 antibody reacts with rat CD90 and mouse CD90.1 (Thy-1.1) (which is expressed by mouse strains of AKR/J, PL, and FVB/N), but not mouse CD90.2.

Additional reported applications (for the relevant formats) include: immunohistochemical7 and immunofluorescent8 staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, immunoprecipitation1, Western blotting1, in vitro activation of leukocytes2, induction of endothelial cell permeability3, induction of apoptosis in glomerular mesangial cells, and induction of glomerulonephritis in vivo4.

Application References

(PubMed link indicates BioLegend citation)
  1. Jeng CJ, et al. 1998. J. Cell Biol. 140:685. (IP, WB)
  2. Nakashima I, et al. 1991. J. Immunol. 147:1153.
  3. Ishizu A, et al. 1995. Int. Immunol. 7:1939.
  4. Eitner F. 1997. Kidney. Int. 51:69.
  5. Kawachi H, et al. 1992. Clin. Exp. Immunol. 88:399. (WB)
  6. Dyer KD, et al. 2007. J. Immunol. 179:1693. (FC) PubMed
  7. Daniel C, et al. 2012. Lab Invest. 92:812. (IHC-P)
  8. Li B, et al. 2006. Kidney Int. 69:323. (ICC)
  9. Uchimura H, et al. 2005. J Am Soc Nephrol. 16(4):997-1004. (IHC-F)
  10. Inagi R, et al. 2008. J Am Soc Nephrol. 19(5):915-22. (IHC-P)
Product Citations
  1. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  2. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  3. Chen M, et al. 2021. Bioact Mater. 1.591666667. PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  6. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  7. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  8. Wang D, et al. 2018. Immunity. 48:659. PubMed
  9. Pack AD, et al. 2021. Cell Reports. 36(8):109586. PubMed
  10. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  11. Lai G, et al. 2022. PeerJ. 10:e13744. PubMed
  12. Nurbaeva MK, et al. 2018. Front Physiol. 0.93125. PubMed
  13. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  14. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  15. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  16. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  17. Olson M, et al. 2012. PLoS Pathog. 8:e1003054. PubMed
  18. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  19. Paschalis E, et al. 2017. Am J Pathol. 10.1016/j.ajpath.2017.02.005. PubMed
  20. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  21. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  22. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  23. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  24. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  25. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  26. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  27. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  28. Alsughayyir J, et al. 2019. Front Immunol. 2.485416667. PubMed
  29. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  30. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  31. Pauken K, et al. 2013. Diabetes. 62:2859. PubMed
  32. Cizkova D, et al. 2014. Sci Rep. 4:7514. PubMed
  33. O’Connor R, et al. 2010. J Immunol. 185:7235. PubMed
  34. Hsu M, et al. 2019. Nat Commun. 10:229. PubMed
RRID
AB_1595635 (BioLegend Cat. No. 202523) AB_1595524 (BioLegend Cat. No. 202524)

Antigen Details

Structure
Ig superfamily, GPI-anchored membrane glycoprotein, 28-30 kD
Distribution

Hematopoietic stem cells, thymocytes, a subset of peripheral blood T cells, early myeloid and erythroid progenitors, immature B cells, neurons, activated endothelium, mast cells, dendritic cells, glomeruli

Function
Adhesion, signal transduction, lymphocyte co-stimulation, proliferation and differentiation of hematopoietic stem cells
Ligand/Receptor
Interacts with CD45
Cell Type
B cells, Dendritic cells, Endothelial cells, Hematopoietic stem and progenitors, Mast cells, Neurons, T cells, Thymocytes
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Campbell DG, et al. 1981. Biochem. J. 195:15.
2. Hosseinzadeh H, et al. 1993. J. Immunol. 150:1670.

Gene ID
21838 View all products for this Gene ID 24832 View all products for this Gene ID
UniProt
View information about CD90/CD90.1 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线